TOTAL VOLUME:
$134b
24H VOL:
$103,397,351
24H TRANSACTIONS:
2,388,728,490
OPEN INTEREST:
$1,410,176,180
399,592
Markets across
30,097
events
MATCHED EVENTS:
2,622
PLATFORM COVERAGE:
5
Polymarket:
39%
VS.
Kalshi:
61%
FDA approves Ionis' Olezarsen?
- Polymarket
FDA approves Ionis' Olezarsen? - Polymarket
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolved Jun 25, 2026
Closed: Jun 29, 8:00 PM EST
Polymarket
Description
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Ionis's Olezarsen as a treatment for severe hypertriglyceridemia by July 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Ionis's Olezarsen as a treatment for severe hypertriglyceridemia by July 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds on Polymarket reflect aggregated trader bets and typically incorporate real-time clinical, regulatory, and competitive data. Analyst forecasts from biotech research firms and investment banks often lag behind market pricing because they update less frequently and may use older trial data or assumptions. The market-implied probability can diverge significantly from published analyst estimates, especially as new clinical readouts or FDA guidance emerges. Comparing the two reveals whether professional consensus aligns with or diverges from decentralized market sentiment on Olezarsen's approval prospects.
The market resolves on Jun 30, 2026, giving traders a window to position ahead of the FDA's final decision on Olezarsen. Resolution hinges on whether the FDA issues an approval letter for this Ionis therapeutic by that date. Any formal FDA approval—standard or accelerated—triggers a YES resolution. Denial, complete refusal to file, or failure to receive a decision by the deadline results in NO. The outcome is binary and determined solely by official FDA action, making regulatory announcements and agency communications critical milestones to monitor.
Key catalysts include new clinical trial data releases, FDA meeting minutes or advisory committee feedback, and competitive approvals in the same therapeutic space. Regulatory letters, complete response letters, or requests for additional information would shift market odds downward. Positive Phase 3 results or breakthrough therapy designation could boost approval odds. Manufacturing or safety updates, management commentary, and peer-reviewed publications on efficacy or safety profiles also influence trader positioning. Broader biotech sentiment, FDA staffing changes, and shifts in regulatory priorities toward rare diseases may create secondary momentum.
